Data Sheet (Cat.No.T36670)

TargetMol

JNJ-67856633

Chemical Properties



CAS No. : 2230273-76-2

Formula: C20H11F6N5O2

Molecular Weight: 467.32

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	JNJ-67856633 is an orally active, first-in-class, potent, selective and allosteric inhibitor of MALT1 protease . JNJ-67856633 lead to tumor stasis in some cases.
Targets(IC50)	MALT
In vitro	JNJ-67856633 is effective and highly bioavailable in both mouse and rat tumors, and in some cases led to tumor stasis. JNJ-67856633 results in potent in vivo pharmacodynamic shutdown in CD79b- as well as CARD11-mutant ABC-DLBCL models as measured by serum IL10 or uncleaved BCL10 levels in tumors[1][3].
In vivo	Treatment with JNJ-67856633 was observed to cause dose-dependent inhibition of Tregs (CD4+CD25+FoxP3+) generation following CD3/28 stimulation, suggesting a potential immune-modulatory role of MALT1 inhibition[3].

Solubility Information

Solubility	DMSO: 125 mg/mL (267.48 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (10.7 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1399 mL	10.6993 mL	21.3986 mL
5 mM	0.428 mL	2.1399 mL	4.2797 mL
10 mM	0.214 mL	1.0699 mL	2.1399 mL
50 mM	0.0428 mL	0.214 mL	0.428 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Virtual meeting delivers first time drug structures
A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants with NHL and CLL
Abstract 5690: Discovery of JNJ-67856633: A novel, first-in-class MALT1 protease inhibitor for the treatment of B cell lymphomas